Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Susana G Rodrigues

Clin Mol Hepatol. 2023;29(1):110-112. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0414

View: 3164 Download: 95 Web of Science: 1 Crossref: 2

Hae Lim Lee, Sung Won Lee

Clin Mol Hepatol. 2022;28(2):121-134. Published online September 27, 2021

DOI: https://doi.org/10.3350/cmh.2021.0239

View: 6004 Download: 360 Web of Science: 15 Crossref: 15

Dongmei Zhao, Guobing Zhang, Mingquan Wang, Chaoxue Zhang, Jiabin Li

Clin Mol Hepatol. 2019;25(2):210-217. Published online March 22, 2019

DOI: https://doi.org/10.3350/cmh.2018.0083

View: 5753 Download: 120 Web of Science: 5 Crossref: 5

Ki Tae Suk

Clin Mol Hepatol. 2014;20(1):6-14. Published online March 26, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.1.6

View: 16739 Download: 354 Web of Science: 92 Crossref: 89

1 |

Viewed By 5169	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5029	MAFLD: How is it different from NAFLD?
Viewed By 4974	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3648	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3619	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Search